The first dual-target CAR-T cell injection developed by the Stone Pharmaceutical Group (01093.HK) based on mRNA-LNP (SYS 6063 injection) has received clinical trial approval in China.

Cnstock News, Stone Pharmaceutical Group (01093.HK) announced that the company's first dual-target chimeric antigen receptor (CAR)-T cell injection liquid based on mRNA-LNP, SYS6063 injection liquid, has been approved by the National Medical Products Administration of the People's Republic of China for clinical trials in China.